(Total Views: 1020)
Posted On: 09/04/2020 10:31:03 PM
Post# of 148905
Re: crazyjogger925 #54271
CJ...Great article, thanks for posting
I love the Investment Summary....
Quote:
INVESTMENT SUMMARY
It’s very clear from these trial results that leronlimab is on the pathway to expedited FDA approval. Within weeks it’s possible if not probable that leronlimab will be the first drug approved in COVID-19. The worldwide pandemic has necessitated the development of a treatment for COVID-19 while the race for vaccine candidates continues as Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), and AstraZeneca (NYSE: AZN) jockey for position. Leronlimab has the ability to get people out of the hospital. It is a simple subcutaneous shot that is very easily administered. Overall it’s a game-changer in the war against COVID-19, and is a much more viable treatment than remdesivir. After the STAT News report, $10 billion of market cap flowed into GILD on news that they had a viable therapeutic. Using this same benchmark for valuation it is anticipated that CYDY will gravitate to the $25 price target as the market anticipates approval. CYDY is not a one trick pony and has a platform technology that would likely expand indications in HIV, cancer, NASH, Multiple Sclerosis, Alzheimer’s, and other immunological diseases. Many of these indications overlap GILD’s current pipeline, perplexing many CYDY shareholders who thought GILD was going to purchase CYDY. It seems clear that CYDY has intentions to develop its own pipeline, forge licensing deals, pursue a NASDAQ listing in the coming weeks, and compete head to head against GILD starting with remdesivir.
I love the Investment Summary....
Quote:
INVESTMENT SUMMARY
It’s very clear from these trial results that leronlimab is on the pathway to expedited FDA approval. Within weeks it’s possible if not probable that leronlimab will be the first drug approved in COVID-19. The worldwide pandemic has necessitated the development of a treatment for COVID-19 while the race for vaccine candidates continues as Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), and AstraZeneca (NYSE: AZN) jockey for position. Leronlimab has the ability to get people out of the hospital. It is a simple subcutaneous shot that is very easily administered. Overall it’s a game-changer in the war against COVID-19, and is a much more viable treatment than remdesivir. After the STAT News report, $10 billion of market cap flowed into GILD on news that they had a viable therapeutic. Using this same benchmark for valuation it is anticipated that CYDY will gravitate to the $25 price target as the market anticipates approval. CYDY is not a one trick pony and has a platform technology that would likely expand indications in HIV, cancer, NASH, Multiple Sclerosis, Alzheimer’s, and other immunological diseases. Many of these indications overlap GILD’s current pipeline, perplexing many CYDY shareholders who thought GILD was going to purchase CYDY. It seems clear that CYDY has intentions to develop its own pipeline, forge licensing deals, pursue a NASDAQ listing in the coming weeks, and compete head to head against GILD starting with remdesivir.
(2)
(0)Scroll down for more posts ▼
